

Emanuela Arvat

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/329828/publications.pdf>

Version: 2024-02-01

141
papers

7,200
citations

61857

43
h-index

64668

79
g-index

143
all docs

143
docs citations

143
times ranked

6300
citing authors

#	ARTICLE	IF	CITATIONS
1	Prognostic Value of Whole-Body PET Volumetric Parameters Extracted from ⁶⁸ Ga-DOTATOC PET/CT in Well-Differentiated Neuroendocrine Tumors. <i>Journal of Nuclear Medicine</i> , 2022, 63, 1014-1020.	2.8	11
2	Development and internal validation of a predictive model for the estimation of pheochromocytoma recurrence risk after radical surgery. <i>European Journal of Endocrinology</i> , 2022, 186, 399-406.	1.9	5
3	Quality of Life during Treatment with Lenvatinib for Thyroid Cancer: The Patients' Perspective beyond the Medical Evaluation. <i>European Thyroid Journal</i> , 2021, 10, 1-7.	1.2	7
4	Real-World Performance of the American Thyroid Association Risk Estimates in Predicting 1-Year Differentiated Thyroid Cancer Outcomes: A Prospective Multicenter Study of 2000 Patients. <i>Thyroid</i> , 2021, 31, 264-271.	2.4	40
5	Malignant struma ovarii: next-generation sequencing of six cases revealed Nras, Braf, and Jak3 mutations. <i>Endocrine</i> , 2021, 71, 216-224.	1.1	12
6	Impact of Allogeneic Stem Cell Transplantation on Testicular and Sexual Function. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 182.e1-182.e8.	0.6	3
7	Diabetes in Cancer Patients: Risks, Goals and Management. <i>Frontiers of Hormone Research</i> , 2021, 54, 1-12.	1.0	5
8	Interventional Radiology Approaches for Liver Metastases from Thyroid Cancer: A Case Series and Overview of the Literature. <i>Journal of Gastrointestinal Cancer</i> , 2021, 52, 823-832.	0.6	6
9	Pituitary metastases from neuroendocrine neoplasms: case report and narrative review. <i>Pituitary</i> , 2021, 24, 828-837.	1.6	6
10	A New Clinical Model to Estimate the Pre-Test Probability of Cushing's Syndrome: The Cushing Score. <i>Frontiers in Endocrinology</i> , 2021, 12, 747549.	1.5	13
11	A Multicenter Epidemiological Study on Second Malignancy in Non-Syndromic Pheochromocytoma/Paraganglioma Patients in Italy. <i>Cancers</i> , 2021, 13, 5831.	1.7	5
12	Nephrotoxicity in advanced thyroid cancer treated with tyrosine kinase inhibitors: An update. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 168, 103533.	2.0	7
13	Predictors of recurrence of pheochromocytoma and paraganglioma: a multicenter study in Piedmont, Italy. <i>Hypertension Research</i> , 2020, 43, 500-510.	1.5	26
14	Symptomatic Biliary Disorders During Lenvatinib Treatment for Thyroid Cancer: An Underestimated Problem. <i>Thyroid</i> , 2020, 30, 229-236.	2.4	14
15	Advanced glycation end products and chronic inflammation in adult survivors of childhood leukemia treated with hematopoietic stem cell transplantation. <i>Pediatric Blood and Cancer</i> , 2020, 67, e28106.	0.8	10
16	The Challenge of Evaluating Response to Peptide Receptor Radionuclide Therapy in Gastroenteropancreatic Neuroendocrine Tumors: The Present and the Future. <i>Diagnostics</i> , 2020, 10, 1083.	1.3	23
17	Perceived impact of diabetes management in patients with cancer: the experience of a tertiary referral center. <i>Zeitschrift Fur Gesundheitswissenschaften</i> , 2020, 29, 903.	0.8	0
18	Modulating tumor reactive stroma by extracorporeal shock waves to control prostate cancer progression. <i>Prostate</i> , 2020, 80, 1087-1096.	1.2	4

#	ARTICLE	IF	CITATIONS
19	Syndrome of inappropriate anti-diuretic hormone secretion in cancer patients: results of the first multicenter Italian study. <i>Therapeutic Advances in Medical Oncology</i> , 2019, 11, 175883591987772.	1.4	16
20	Benzene affects the response to octreotide treatment of growth hormone secreting pituitary adenoma cells. <i>Environmental Research</i> , 2019, 173, 489-496.	3.7	3
21	HypoparaNet: A Database of Chronic Hypoparathyroidism Based on Expert Medical-Surgical Centers in Italy. <i>Calcified Tissue International</i> , 2018, 103, 151-163.	1.5	23
22	The utility of blood neuroendocrine gene transcript measurement in the diagnosis of bronchopulmonary neuroendocrine tumours and as a tool to evaluate surgical resection and disease progression. <i>European Journal of Cardio-thoracic Surgery</i> , 2018, 53, 631-639.	0.6	35
23	Craniopharyngioma and Posttreatment Pituitary Dysfunction in Brain Tumors. <i>Endocrinology</i> , 2018, , 129-160.	0.1	0
24	Diagnostic evaluation in steroid-induced myopathy: case report suggesting clinical utility of quantitative muscle ultrasonography. <i>Endocrine Research</i> , 2018, 43, 235-245.	0.6	5
25	Adverse glycaemic effects of cancer therapy: indications for a rational approach to cancer patients with diabetes. <i>Metabolism: Clinical and Experimental</i> , 2018, 78, 141-154.	1.5	47
26	Diagnostic work-up in steroid myopathy. <i>Endocrine</i> , 2018, 60, 219-223.	1.1	33
27	Craniopharyngioma and Posttreatment Pituitary Dysfunction in Brain Tumors. <i>Endocrinology</i> , 2018, , 1-32.	0.1	0
28	Fibulin-1 interacts with Sex Hormone Binding Globulin and is linked to less aggressive estrogen-dependent breast cancers. <i>Life Sciences</i> , 2018, 207, 372-380.	2.0	4
29	Prognostic factors in ectopic Cushing's syndrome due to neuroendocrine tumors: a multicenter study. <i>European Journal of Endocrinology</i> , 2017, 176, 453-461.	1.9	66
30	Long-Term Outcomes of Adjuvant Mitotane Therapy in Patients With Radically Resected Adrenocortical Carcinoma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017, 102, 1358-1365.	1.8	108
31	Tyrosine kinase inhibitors rechallenge in solid tumors: a review of literature and a case description with lenvatinib in thyroid cancer. <i>Expert Review of Anticancer Therapy</i> , 2017, 17, 1093-1098.	1.1	23
32	Are Evidence-Based Guidelines Reflected in Clinical Practice? An Analysis of Prospectively Collected Data of the Italian Thyroid Cancer Observatory. <i>Thyroid</i> , 2017, 27, 1490-1497.	2.4	52
33	Effects of environmental pollutants on signaling pathways in rat pituitary GH3 adenoma cells. <i>Environmental Research</i> , 2017, 158, 660-668.	3.7	19
34	The Functional and Clinical Significance of the 24-Hour Rhythm of Circulating Glucocorticoids. <i>Endocrine Reviews</i> , 2017, 38, 3-45.	8.9	353
35	Efficacy of triamcinolone acetate and methylprednisolone acetonide for intrabursal injection after ultrasound-guided percutaneous treatment in painful shoulder calcific tendonitis: a randomized controlled trial. <i>Acta Radiologica</i> , 2017, 58, 964-970.	0.5	9
36	Valproic Acid, a Histone Deacetylase Inhibitor, in Combination with Paclitaxel for Anaplastic Thyroid Cancer: Results of a Multicenter Randomized Controlled Phase II/III Trial. <i>International Journal of Endocrinology</i> , 2016, 2016, 1-8.	0.6	25

#	ARTICLE	IF	CITATIONS
37	The Mineralocorticoid Agonist Fludrocortisone Promotes Survival and Proliferation of Adult Hippocampal Progenitors. <i>Frontiers in Endocrinology</i> , 2016, 7, 66.	1.5	17
38	<scp>ACROSCORE</scp>: a new and simple tool for the diagnosis of acromegaly, a rare and underdiagnosed disease. <i>Clinical Endocrinology</i> , 2016, 84, 380-385.	1.2	24
39	Clinical challenges with calcitonin-negative medullary thyroid carcinoma. <i>Journal of Cancer Research and Clinical Oncology</i> , 2016, 142, 2023-2029.	1.2	30
40	GH deficiency in adult survivors of childhood cancer. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2016, 30, 795-804.	2.2	9
41	Diabetology and oncology meet in a network model: union is strength. <i>Acta Diabetologica</i> , 2016, 53, 515-524.	1.2	20
42	Improvement of anthropometric and metabolic parameters, and quality of life following treatment with dual-release hydrocortisone in patients with Addisonâ€™s disease. <i>Endocrine</i> , 2016, 51, 360-368.	1.1	78
43	Hypothalamic-Pituitary Autoimmunity and Traumatic Brain Injury. <i>Journal of Clinical Medicine</i> , 2015, 4, 1025-1035.	1.0	26
44	Cushingâ€™s syndrome is associated with sleep alterations detected by wrist actigraphy. <i>Pituitary</i> , 2015, 18, 893-897.	1.6	14
45	Meningiomas after cranial radiotherapy for childhood cancer: a single institution experience. <i>Journal of Cancer Research and Clinical Oncology</i> , 2015, 141, 1277-1282.	1.2	18
46	Sorafenib treatment of radioiodine-refractory advanced thyroid cancer in daily clinical practice: a cohort study from a single center. <i>Endocrine</i> , 2015, 49, 726-734.	1.1	12
47	Enhanced oxidative stress and platelet activation in patients with Cushing's syndrome. <i>Clinical Endocrinology</i> , 2015, 82, 517-524.	1.2	30
48	Prevalence of cardiovascular risk factors in long-term survivors of childhood cancer: 16 years follow up from a prospective registry. <i>European Journal of Preventive Cardiology</i> , 2015, 22, 762-770.	0.8	32
49	Pituitary lesions in breast cancer patients: A report of three cases. <i>Oncology Letters</i> , 2015, 9, 2762-2766.	0.8	14
50	Early Surgery and Survival of Patients with Anaplastic Thyroid Carcinoma: Analysis of a Case Series Referred to a Single Institution Between 1999 and 2012. <i>Thyroid</i> , 2014, 24, 1600-1606.	2.4	57
51	Urinary cortisol and psychopathology in obese binge eating subjects. <i>Appetite</i> , 2014, 83, 112-116.	1.8	13
52	Identification of risk conditions for the development of adrenal disorders: how optimized PubMed search strategies makes the difference. <i>Endocrine</i> , 2014, 47, 734-739.	1.1	0
53	PubMed search strategies for the identification of etiologic associations between hypothalamic-pituitary disorders and other medical conditions. <i>Pituitary</i> , 2013, 16, 471-482.	1.6	2
54	Acute administration of alprazolam, a benzodiazepine activating GABA receptors, inhibits cortisol secretion in patients with subclinical but not overt Cushingâ€™s syndrome. <i>Pituitary</i> , 2013, 16, 363-369.	1.6	2

#	ARTICLE	IF	CITATIONS
55	The acute effect of fludrocortisone on basal and hCRH-stimulated hypothalamic-pituitary-adrenal (HPA) axis in humans. <i>Pituitary</i> , 2013, 16, 378-385.	1.6	12
56	Role of mineralocorticoid receptors on the hypothalamus-pituitary-adrenal axis in humans. <i>Endocrine</i> , 2013, 43, 51-58.	1.1	53
57	BC polymorphism of the glucocorticoid receptor gene is associated with increased obesity, impaired glucose metabolism and dyslipidaemia in patients with Addison's disease. <i>Clinical Endocrinology</i> , 2012, 77, 863-870.	1.2	42
58	Potential Role for Retinoic Acid in Patients with Cushing's Disease. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012, 97, 3577-3583.	1.8	105
59	Glucose metabolism in patients with subclinical Cushing's syndrome. <i>Endocrine</i> , 2012, 41, 415-423.	1.1	54
60	Metabolic and cardiovascular outcomes in patients with Cushing's syndrome of different aetiologies during active disease and 1 year after remission. <i>Clinical Endocrinology</i> , 2011, 75, 354-360.	1.2	89
61	Detection of antipituitary and antihypothalamus antibodies to investigate the role of pituitary or hypothalamic autoimmunity in patients with selective idiopathic hypopituitarism. <i>Clinical Endocrinology</i> , 2011, 75, 361-366.	1.2	56
62	Do muscle fiber conduction slowing and decreased levels of circulating muscle proteins represent sensitive markers of steroid myopathy? A pilot study in Cushing's disease. <i>European Journal of Endocrinology</i> , 2011, 164, 985-993.	1.9	33
63	Effects of cetrorelix, a GnRH-receptor antagonist, on gonadal axis in women with functional hypothalamic amenorrhea. <i>Gynecological Endocrinology</i> , 2011, 27, 753-758.	0.7	4
64	Dual-release Hydrocortisone in Addison's Disease - A Review of the Literature. <i>European Endocrinology</i> , 2010, 10, 75.	0.8	3
65	Cytotoxic T lymphocyte antigen-4 Ala17 polymorphism is a genetic marker of autoimmune adrenal insufficiency: Italian association study and meta-analysis of European studies. <i>European Journal of Endocrinology</i> , 2010, 162, 361-369.	1.9	35
66	Effect of acute and prolonged mineralocorticoid receptor blockade on spontaneous and stimulated hypothalamic-pituitary-adrenal axis in humans. <i>European Journal of Endocrinology</i> , 2010, 162, 1067-1074.	1.9	26
67	Neuroendocrine Alterations in Obese Patients with Sleep Apnea Syndrome. <i>International Journal of Endocrinology</i> , 2010, 2010, 1-11.	0.6	58
68	Muscle Fiber Conduction Slowing and Decreased Levels of Circulating Muscle Proteins after Short-Term Dexamethasone Administration in Healthy Subjects. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2010, 95, 1663-1671.	1.8	34
69	Endocrine actions of cortistatin: In vivo studies. <i>Molecular and Cellular Endocrinology</i> , 2008, 286, 123-127.	1.6	34
70	Adjuvant Mitotane Treatment for Adrenocortical Carcinoma. <i>New England Journal of Medicine</i> , 2007, 356, 2372-2380.	13.9	679
71	Neuroregulation of the Hypothalamus-Pituitary-Adrenal (HPA) Axis in Humans: Effects of GABA-, Mineralocorticoid-, and GH-Secretagogue-Receptor Modulation. <i>Scientific World Journal</i> , The, 2006, 6, 1-11.	0.8	53
72	Endocrine Function Is Altered in Chronic Migraine Patients with Medication-Overuse. <i>Headache</i> , 2006, 46, 597-603.	1.8	37

#	ARTICLE	IF	CITATIONS
73	Effect of protracted treatment with rosiglitazone, a PPAR γ agonist, in patients with Cushing's disease. <i>Clinical Endocrinology</i> , 2006, 64, 219-224.	1.2	80
74	Neuroendocrine effects of citalopram infusion in anorexia nervosa. <i>Psychoneuroendocrinology</i> , 2006, 31, 1139-1148.	1.3	8
75	Dehydroepiandrosterone sulfate (DHEA-S) and Alzheimer's dementia in older subjects. <i>International Journal of Geriatric Psychiatry</i> , 2006, 21, 1065-1070.	1.3	15
76	Effects of free fatty acids on ACTH and cortisol secretion in anorexia nervosa. <i>European Journal of Endocrinology</i> , 2006, 154, 731-738.	1.9	10
77	Corticotrope hypersecretion coupled with cortisol hypo-responsiveness to stimuli is present in patients with autoimmune endocrine diseases: evidence for subclinical primary hypoadrenalism?. <i>European Journal of Endocrinology</i> , 2006, 155, 421-428.	1.9	14
78	Hypothalamus-Pituitary-Adrenal Hyperactivity in Human Aging Is Partially Refractory to Stimulation by Mineralocorticoid Receptor Blockade. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2005, 90, 5656-5662.	1.8	54
79	The negative association between total ghrelin levels, body mass and insulin secretion is lost in hypercortisolemic patients with Cushing's disease. <i>European Journal of Endocrinology</i> , 2005, 153, 535-543.	1.9	16
80	Testing Pituitary Function in Aging Individuals. <i>Endocrinology and Metabolism Clinics of North America</i> , 2005, 34, 895-906.	1.2	8
81	Free Fatty Acids Exert an Inhibitory Effect on Adrenocorticotropin and Cortisol Secretion in Humans. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2004, 89, 1385-1390.	1.8	40
82	Ghrelin does not mediate the somatotroph and corticotroph responses to the stimulatory effect of glucagon or insulin-induced hypoglycaemia in humans. <i>Clinical Endocrinology</i> , 2004, 60, 699-704.	1.2	17
83	Ghrelin secretion is inhibited by glucose load and insulin-induced hypoglycaemia but unaffected by glucagon and arginine in humans. <i>Clinical Endocrinology</i> , 2004, 61, 503-509.	1.2	65
84	Ghrelin, Hypothalamus-Pituitary-Adrenal (HPA) Axis and Cushing's Syndrome. <i>Pituitary</i> , 2004, 7, 243-248.	1.6	45
85	Acetylcholine Regulates Ghrelin Secretion in Humans. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2004, 89, 2429-2433.	1.8	98
86	Acetylcholine does not play a major role in mediating the endocrine responses to ghrelin, a natural ligand of the GH secretagogue receptor, in humans. <i>Clinical Endocrinology</i> , 2003, 58, 92-98.	1.2	21
87	Alprazolam (a benzodiazepine activating GABA receptor) reduces the neuroendocrine responses to insulin-induced hypoglycaemia in humans. <i>Clinical Endocrinology</i> , 2003, 59, 314-320.	1.2	32
88	Hypopituitary patients with corticotropin insufficiency show marked impairment of the cortisol response to ACTH (1 μ g \times 24) independently of the duration of the disease. <i>Journal of Endocrinological Investigation</i> , 2003, 26, 49-55.	1.8	34
89	The Endocrine Response to Ghrelin as a Function of Gender in Humans in Young and Elderly Subjects. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2003, 88, 1537-1542.	1.8	196
90	Endocrine and Non-Endocrine Actions of Ghrelin. <i>Hormone Research in Paediatrics</i> , 2003, 59, 109-117.	0.8	64

#	ARTICLE	IF	CITATIONS
91	Endocrine Activities of Cortistatin-14 and Its Interaction with GHRH and Ghrelin in Humans. Journal of Clinical Endocrinology and Metabolism, 2002, 87, 3783-3790.	1.8	72
92	Ghrelin Secretion Is Inhibited by Either Somatostatin or Cortistatin in Humans. Journal of Clinical Endocrinology and Metabolism, 2002, 87, 4829-4832.	1.8	152
93	Ghrelin Is No Longer Able to Stimulate Growth Hormone Secretion in Patients with Cushing's Syndrome but Instead Induces Exaggerated Corticotropin and Cortisol Responses. Neuroendocrinology, 2002, 76, 390-396.	1.2	48
94	Ghrelin and synthetic GH secretagogues. Best Practice and Research in Clinical Endocrinology and Metabolism, 2002, 16, 505-517.	2.2	23
95	The GH-releasing effect of ghrelin, a natural GH secretagogue, is only blunted by the infusion of exogenous somatostatin in humans. Clinical Endocrinology, 2002, 56, 643-648.	1.2	77
96	Endocrine responses to ghrelin in adult patients with isolated childhood-onset growth hormone deficiency. Clinical Endocrinology, 2002, 56, 765-771.	1.2	29
97	Effects of glucose, free fatty acids or arginine load on the GH-releasing activity of ghrelin in humans. Clinical Endocrinology, 2002, 57, 265-271.	1.2	56
98	Dehydroepiandrosterone, 17 β -hydroxyprogesterone and aldosterone responses to the low-dose (1 μ g) ACTH test in subjects with preclinical adrenal autoimmunity. Clinical Endocrinology, 2002, 57, 677-683.	1.2	24
99	Biologic Activities of Growth Hormone Secretagogues in Humans. Endocrine, 2001, 14, 087-093.	2.2	112
100	Ghrelin, a Natural GH Secretagogue Produced by the Stomach, Induces Hyperglycemia and Reduces Insulin Secretion in Humans. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 5083-5083.	1.8	603
101	Elderly subjects show severe impairment of dehydroepiandrosterone sulphate and reduced sensitivity of cortisol and aldosterone response to the stimulatory effect of ACTH $_{1-24}$. Clinical Endocrinology, 2001, 55, 259-265.	1.2	35
102	Effect of digoxin on the somatotroph responsiveness to growth hormone-releasing hormone (GHRH) alone or combined with arginine in normal young volunteers. Clinical Endocrinology, 2001, 55, 755-758.	1.2	2
103	Growth Hormone-Releasing Hormone and Growth Hormone Secretagogue-Receptor Ligands. Endocrine, 2001, 14, 035-043.	2.2	11
104	Growth Hormone-Independent Cardiotropic Activities of Growth Hormone-Releasing Peptides in Normal Subjects, in Patients with Growth Hormone Deficiency, and in Patients with Idiopathic or Ischemic Dilated Cardiomyopathy. Endocrine, 2001, 14, 105-108.	2.2	27
105	Growth Hormone-Releasing Hormone Combined with Arginine or Growth Hormone Secretagogues for the Diagnosis of Growth Hormone Deficiency in Adults. Endocrine, 2001, 15, 029-038.	2.2	86
106	Mineralocorticoid Receptor Blockade by Canrenoate Increases Both Spontaneous and Stimulated Adrenal Function in Humans. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 3176-3181.	1.8	43
107	Endocrine Activities of Ghrelin, a Natural Growth Hormone Secretagogue (GHS), in Humans: Comparison and Interactions with Hexarelin, a Nonnatural Peptidyl GHS, and GH-Releasing Hormone. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 1169-1174.	1.8	428
108	Effects of free fatty acids and acipimox, a lipolysis inhibitor, on the somatotroph responsiveness to GHRH in anorexia nervosa. Clinical Endocrinology, 2000, 52, 713-720.	1.2	10

#	ARTICLE	IF	CITATIONS
109	Low dose (1â€µg) ACTH test in the evaluation of adrenal dysfunction in pre-clinical Addison's disease. <i>Clinical Endocrinology</i> , 2000, 53, 107-115.	1.2	55
110	Glucagon is an ACTH secretagogue as effective as hCRH after intramuscular administration while it is ineffective when given intravenously in normal subjects. <i>Pituitary</i> , 2000, 3, 169-173.	1.6	16
111	Hypothalamic Growth Hormone-Insulin-like Growth Factor-I Axis across the Human Life Span. <i>Journal of Pediatric Endocrinology and Metabolism</i> , 2000, 13, 1493-1502.	0.4	29
112	Effects of Recombinant Human Insulin-Like Growth Factor I Administration on Spontaneous and Growth Hormone (GH)-Releasing Hormone-Stimulated GH Secretion in Anorexia Nervosa ¹ . <i>Journal of Clinical Endocrinology and Metabolism</i> , 2000, 85, 2805-2809.	1.8	30
113	Stimulatory Effect of Adrenocorticotropin on Cortisol, Aldosterone, and Dehydroepiandrosterone Secretion in Normal Humans: Dose-Response Study*. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2000, 85, 3141-3146.	1.8	86
114	Arginine Counteracts the Inhibitory Effect of Recombinant Human Insulin-Like Growth Factor I on the Somatotroph Responsiveness to Growth Hormone-Releasing Hormone in Humans ¹ . <i>Journal of Clinical Endocrinology and Metabolism</i> , 2000, 85, 3604-3608.	1.8	25
115	Insulin-Like Growth Factor I. <i>Drugs and Aging</i> , 2000, 16, 29-40.	1.3	68
116	GH Secretagogues in Aging. <i>Rejuvenation Research</i> , 2000, 3, 149-158.	0.2	7
117	The Inhibitory Effect of Alprazolam, a Benzodiazepine, Overrides the Stimulatory Effect of Metyrapone-Induced Lack of Negative Cortisol Feedback on Corticotroph Secretion in Humans ¹ . <i>Journal of Clinical Endocrinology and Metabolism</i> , 1999, 84, 2611-2615.	1.8	26
118	Endocrine and Non-Endocrine Activities of Growth Hormone Secretagogues in Humans. <i>Hormone Research in Paediatrics</i> , 1999, 51, 9-15.	0.8	36
119	Activity of GH/IGF-I axis in patients with dilated cardiomyopathy. <i>Clinical Endocrinology</i> , 1999, 50, 417-430.	1.2	61
120	Effects of alprazolam, a benzodiazepine, on the ACTH-, GH- and PRL-releasing activity of hexarelin, a synthetic peptidyl GH secretagogue (GHS), in patients with simple obesity and in patients with Cushing's disease. <i>Pituitary</i> , 1999, 2, 197-204.	1.6	10
121	Effect of somatostatin infusion on the somatotrope responsiveness to growth hormone-releasing hormone in patients with anorexia nervosa. <i>Biological Psychiatry</i> , 1999, 45, 334-339.	0.7	18
122	Corticotropin-Releasing Effect of Hexarelin, a Peptidyl GH Secretagogue, in Normal Subjects Pretreated with Metyrapone or RU-486, a Glucocorticoid Receptor Antagonist, and in Patients with Addison's Disease. <i>Neuroendocrinology</i> , 1999, 70, 200-206.	1.2	14
123	Endocrine Responses to GH Secretagogues in Relation to Sex and Age in Humans. , 1999, , 249-260.		1
124	Hormonal Activities of Growth Hormone Secretagogues (GHS) across Human Lifespan. , 1999, , 139-155.		3
125	Growth Hormone-Releasing Peptides and Their Analogs. <i>Frontiers in Neuroendocrinology</i> , 1998, 19, 47-72.	2.5	80
126	The IGF-I response to very low rhGH doses is preserved in human ageing. <i>Clinical Endocrinology</i> , 1998, 49, 757-763.	1.2	31

#	ARTICLE	IF	CITATIONS
127	10 Diagnostic and therapeutic uses of growth hormone-releasing substances in adult and elderly subjects. <i>Bailliere's Clinical Endocrinology and Metabolism</i> , 1998, 12, 341-358.	1.0	38
128	Effects of beta-adrenergic agonists and antagonists on the growth hormone response to growth hormone-releasing hormone in anorexia nervosa. <i>Biological Psychiatry</i> , 1998, 43, 181-187.	0.7	18
129	Orally active growth hormone secretagogues: state of the art and clinical perspectives. <i>Annals of Medicine</i> , 1998, 30, 159-168.	1.5	45
130	Effects of Dexamethasone and Alprazolam, a Benzodiazepine, on the Stimulatory Effect of Hexarelin, a Synthetic GHRP, on ACTH, Cortisol and GH Secretion in Humans. <i>Neuroendocrinology</i> , 1998, 67, 310-316.	1.2	51
131	Hexarelin, a Synthetic Growth-Hormone Releasing Peptide, Shows No Interaction with Corticotropin-Releasing Hormone and Vasopressin on Adrenocorticotropin and Cortisol Secretion in Humans. <i>Neuroendocrinology</i> , 1997, 66, 432-438.	1.2	43
132	Mechanisms underlying the negative growth hormone (GH) autofeedback on the GH-releasing effect of hexarelin in man. <i>Metabolism: Clinical and Experimental</i> , 1997, 46, 83-88.	1.5	36
133	Effects of GHRP-2 and Hexarelin, Two Synthetic GH-Releasing Peptides, on GH, Prolactin, ACTH and Cortisol Levels in Man. Comparison with the Effects of GHRH, TRH and hCRH. <i>Peptides</i> , 1997, 18, 885-891.	1.2	78
134	New approach to the diagnosis of growth hormone deficiency in adults. <i>European Journal of Endocrinology</i> , 1996, 134, 352-356.	1.9	248
135	Somatotrope responsiveness to Hexarelin, a synthetic hexapeptide, is refractory to the inhibitory effect of glucose in obesity. <i>European Journal of Endocrinology</i> , 1996, 135, 678-682.	1.9	15
136	Ageing and Growth Hormone Releasing Peptides. , 1996, , 415-431.		8
137	Modulation of Growth Hormone-Releasing Activity of Hexarelin in Man. <i>Neuroendocrinology</i> , 1995, 61, 51-56.	1.2	71
138	Involvement of Brain Catecholamines and Acetylcholine in Growth Hormone Hypersecretory States. <i>Drugs</i> , 1995, 50, 805-837.	4.9	32
139	Effects of direct and indirect acetylcholine receptor agonists on growth hormone secretion in humans. <i>European Journal of Pharmacology</i> , 1994, 254, 17-20.	1.7	7
140	Arginine Reinstates the Somatotrope Responsiveness to Intermittent Growth Hormone-Releasing Hormone Administration in Normal Adults. <i>Neuroendocrinology</i> , 1991, 54, 291-294.	1.2	90
141	Growth Hormone (GH) Responsiveness to Combined Administration of Arginine and GH-Releasing Hormone Does not Vary with Age in Man*. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1990, 71, 1481-1485.	1.8	162